HAHalozyme Therapeutics HALO · NASDAQ
$122.50 +0.54% (+$0.66)
- Market cap
- $13.8B
- Enterprise value
- $15.8B
- P/E
- 33.4x
- Forward P/E
- 12.9x
- PEG
- -
- P/S
- 8.3x
- P/FCF
- 17.2x
- EV/EBITDA
- 22.1x
- ROIC
- 27.4%
- Gross margin
- 78.2%
- Net margin
- 24.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 2.8x
- Beta
- 0.88
- Free float
- 98.9%
About the company
Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing innovative therapeutic agents and technologies that improve drug absorption. Founded in 1998 and headquartered in San Diego, California, Halozyme is best known for its Enhanze™ platform, which uses enzymes to accelerate the absorption of biologic drugs, enabling them to be administered in lower doses or over shorter periods. The company collaborates with numerous pharmaceutical and biotechnology firms to develop new therapeutic products.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen I. Torley
Employees
423
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number